Viatris (VTRS) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $0.71
- Estimate
- $0.64
- Surprise
- +11.3%
- Revenue (period 2026-09-30)
- $3.73B
- Score today
- 5.5/10
Revenue source: xbrl.
How the report landed
Viatris (VTRS) beat the $0.64 estimate with adjusted EPS of $0.71 — a large 11.3% upside surprise.
Coverage in the report window
- Jefferies Adjusts Viatris Price Target — fiscal.ai, 2026-11-06
- Viatris Q3 2026 Earnings Call Transcript — benzinga, 2026-11-05
- Viatris Reports Q3 2026 Financial Results and Raises 2026 Guidance — fiscal.ai, 2026-11-05
Where TrendMatrix's rating stands now
TrendMatrix currently rates VTRS Sell at 5.5/10; no pre/post engine snapshot brackets this report.
4 of the last 4 quarters beat the estimate; this quarter's +11.3% surprise compares with a +12.8% four-quarter average.
What argues against it
- Target reached (-10.6% upside)
- Quality below floor (3.9 < 4.0)
- Negative risk/reward — downside exceeds upside
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $19.45
- Stop
- $18.39
Model outputs from TrendMatrix’s engine as of 2026-11-06 — shown for context, not personalized investment advice.
VTRS at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Drug Manufacturers - Specialty & Generic
- Market cap
- $21.79B
- P/E (fwd)
- 7.0
- 52-week range
- $9.92–$19.96
- Off 52-week high
- 2.5%
- RSI (14)
- 65
- Volume vs avg
- 0.35×
- Score today
- 5.5/10